Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 171

1.

Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.

Cassidy TA, Thorley E, Black RA, DeVeaugh-Geiss A, Butler SF, Coplan P.

J Opioid Manag. 2017 Nov/Dec;13(6):425-440. doi: 10.5055/jom.2017.0419.

PMID:
29308589
2.

A Phase I study of the pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxymorphone transdermal patch system.

Gavin PD, Simon LS, Schlagheck T, Smith AJ, Krishnarajah J.

Pain Manag. 2017 Nov;7(6):499-512. doi: 10.2217/pmt-2017-0032. Epub 2017 Aug 17.

PMID:
28814158
3.

Oxymorphone Hydrochloride Extended-Release (OPANA®) Associated With Acute Kidney Injury in a Chronic Pain Patient: A Case Report.

Yatsynovich Y, Souza D, Maroz N.

A A Case Rep. 2017 Dec 1;9(11):324-327. doi: 10.1213/XAA.0000000000000607.

PMID:
28786851
4.

Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone.

Robson KJ, Clucas D, Filshie R, Nandurkar H.

BMJ Case Rep. 2017 Jul 17;2017. pii: bcr-2017-220977. doi: 10.1136/bcr-2017-220977.

PMID:
28716778
5.

Ketorolac, Oxymorphone, Tapentadol, and Tramadol: A Comprehensive Review.

Vadivelu N, Chang D, Helander EM, Bordelon GJ, Kai A, Kaye AD, Hsu D, Bang D, Julka I.

Anesthesiol Clin. 2017 Jun;35(2):e1-e20. doi: 10.1016/j.anclin.2017.01.001. Epub 2017 Apr 14. Review.

PMID:
28526155
6.

Analysis of Intensive Care Unit Admission and Sequelae in Patients Intravenously Abusing Extended-Release Oral Oxymorphone.

Wilson MW, Bonnecaze AK, Dharod A, Miller PJ.

South Med J. 2017 Mar;110(3):217-222. doi: 10.14423/SMJ.0000000000000624.

PMID:
28257549
7.

Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.

Healy JR, Bezawada P, Griggs NW, Devereaux AL, Matsumoto RR, Traynor JR, Coop A, Cunningham CW.

Bioorg Med Chem Lett. 2017 Feb 1;27(3):666-669. doi: 10.1016/j.bmcl.2016.11.057. Epub 2016 Nov 22.

8.

A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER.

Hunt R, Yalamanoglu A, Tumlin J, Schiller T, Baek JH, Wu A, Fogo AB, Yang H, Wong E, Miller P, Buehler PW, Kimchi-Sarfaty C.

Blood. 2017 Feb 16;129(7):896-905. doi: 10.1182/blood-2016-08-736579. Epub 2016 Nov 18.

9.

Effect of morphine, methadone, hydromorphone or oxymorphone on the thermal threshold, following intravenous or buccal administration to cats.

Pypendop BH, Shilo-Benjamini Y, Ilkiw JE.

Vet Anaesth Analg. 2016 Nov;43(6):635-642. doi: 10.1111/vaa.12356. Epub 2016 Mar 1.

PMID:
27723230
10.

New Initiation of Long-Acting Opioids in Long-Stay Nursing Home Residents.

Pimentel CB, Gurwitz JH, Tjia J, Hume AL, Lapane KL.

J Am Geriatr Soc. 2016 Sep;64(9):1772-8. doi: 10.1111/jgs.14306. Epub 2016 Aug 3.

11.

HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015.

Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, Blosser SJ, Spiller MW, Combs B, Switzer WM, Conrad C, Gentry J, Khudyakov Y, Waterhouse D, Owen SM, Chapman E, Roseberry JC, McCants V, Weidle PJ, Broz D, Samandari T, Mermin J, Walthall J, Brooks JT, Duwve JM; Indiana HIV Outbreak Investigation Team.

N Engl J Med. 2016 Jul 21;375(3):229-39. doi: 10.1056/NEJMoa1515195.

12.

Prescription Opioids. V. Metabolism and Excretion of Oxymorphone in Urine Following Controlled Single Dose Administration.

DePriest AZ, Heltsley R, Black DL, Mitchell JM, LoDico C, Flegel R, Cone EJ.

J Anal Toxicol. 2016 Oct;40(8):566-574. Epub 2016 Jul 11.

PMID:
27405370
13.

A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.

Cicero TJ, Ellis MS, Kasper ZA.

Pain. 2016 Jun;157(6):1232-8. doi: 10.1097/j.pain.0000000000000511.

PMID:
27186712
14.

THROMBOTIC MICROANGIOPATHY ASSOCIATED WITH OPANA ER INTRAVENOUS ABUSE A Case Report.

Jabr FI, Yu L.

J Med Liban. 2016 Jan-Mar;64(1):40-2.

PMID:
27169165
15.

Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.

Walter C, Knothe C, Lötsch J.

Clin Pharmacokinet. 2016 Jul;55(7):751-767. doi: 10.1007/s40262-015-0362-3. Review.

PMID:
26719075
16.

Commentary.

Garg M, Davis L.

Ann Emerg Med. 2015 Sep;66(3):316-7. doi: 10.1016/j.annemergmed.2015.05.032. No abstract available.

PMID:
26304250
17.

Acute Sensorineural Hearing Loss After Abuse of an Inhaled, Crushed Oxymorphone Extended-Release Tablet.

MacDonald LE, Onsrud JE, Mullins-Hodgin R.

Pharmacotherapy. 2015 Jul;35(7):e118-21. doi: 10.1002/phar.1605. Epub 2015 Jun 25.

PMID:
26112082
18.

Effects of oxymorphone hydrochloride or hydromorphone hydrochloride on minimal alveolar concentration of desflurane in sheep.

Sayre RS, Lepiz MA, Horsley KT, Pashmakova MB, Barr JW, Washburn SE.

Am J Vet Res. 2015 Jul;76(7):583-90. doi: 10.2460/ajvr.76.7.583.

PMID:
26111087
19.

A case of rhabdomyolysis associated with severe opioid withdrawal.

Gangahar D.

Am J Addict. 2015 Aug;24(5):400-2. doi: 10.1111/ajad.12255. Epub 2015 Jun 22.

PMID:
26095066
20.

Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone--Indiana, 2015.

Conrad C, Bradley HM, Broz D, Buddha S, Chapman EL, Galang RR, Hillman D, Hon J, Hoover KW, Patel MR, Perez A, Peters PJ, Pontones P, Roseberry JC, Sandoval M, Shields J, Walthall J, Waterhouse D, Weidle PJ, Wu H, Duwve JM; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2015 May 1;64(16):443-4.

Supplemental Content

Loading ...
Support Center